U.S. Stem Cell, Inc.

$ Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000118518523000339 Filed on April 14, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022

Balance Sheet

Concept	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.130K	$5.130K
YoY Change	-86.98%	-86.98%
Cash & Equivalents	$5.133K	$5.130K
Short-Term Investments
Other Short-Term Assets	$57.59K	$57.59K
YoY Change	475.9%	475.9%
Inventory	$980.00	$980.00
Prepaid Expenses
Receivables	$4.332K	$4.330K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$68.04K	$68.04K
YoY Change	33.41%	33.41%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$68.04K	$68.04K
Total Long-Term Assets	$0.00	$0.00
Total Assets	$68.04K	$68.04K
YoY Change	33.41%	33.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.625M	$1.625M
YoY Change	18.29%	18.29%
Accrued Expenses	$2.583M	$2.583M
YoY Change	32.34%	32.34%
Deferred Revenue
YoY Change
Short-Term Debt	$4.285M	$4.285M
YoY Change	28.35%	28.35%
Long-Term Debt Due	$3.980M	$3.980M
YoY Change	0.61%	0.61%
Total Short-Term Liabilities	$14.08M	$14.08M
YoY Change	16.94%	16.94%
LONG-TERM LIABILITIES
Long-Term Debt	$682.0K	$682.0K
YoY Change	-5.54%	-5.54%
Other Long-Term Liabilities	$53.50K	$53.50K
YoY Change	-5.31%	-5.31%
Total Long-Term Liabilities	$735.5K	$735.5K
YoY Change	-5.53%	-5.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.08M	$14.08M
Total Long-Term Liabilities	$735.5K	$735.5K
Total Liabilities	$14.81M	$14.81M
YoY Change	15.57%	15.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$142.5M
YoY Change	1.94%
Common Stock	$634.4K
YoY Change	25.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$14.75M	-$14.75M
YoY Change
Total Liabilities & Shareholders Equity	$68.04K	$68.04K
YoY Change	33.41%	33.41%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Security Exchange Name SecurityExchangeName	NONE
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity Registrant Name EntityRegistrantName	U.S. STEM CELL, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2022	dei	Entity File Number EntityFileNumber	001-33718
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0945967
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1560 Sawgrass Corporate Pkwy
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	4th Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Sunrise
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33323
CY2022	dei	City Area Code CityAreaCode	954
CY2022	dei	Local Phone Number LocalPhoneNumber	835-1500
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022	dei	Trading Symbol TradingSymbol	USRM
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	2376858	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	641507317	shares
CY2022	dei	Auditor Firm AuditorFirmId	587
CY2022	dei	Auditor Name AuditorName	RBSM LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57594	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39393	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	75000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	75000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4332	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1213	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	980	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	393	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5133	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	68039	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	50999	usd
CY2022Q4	us-gaap	Assets Assets	68039	usd
CY2021Q4	us-gaap	Assets Assets	50999	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1624583	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1373413	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2582559	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1951390	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1137642	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	951432	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3000	usd
CY2022Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	465286	usd
CY2021Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	465286	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	3894200	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	3144200	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2582083	usd
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2557881	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1397762	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1397762	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	390776	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	194411	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14077891	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12038775	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	53500	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	56500	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	11059	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	21575	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	682044	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	722060	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	735544	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	778560	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14813435	usd
CY2021Q4	us-gaap	Liabilities Liabilities	12817335	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	634402623	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	231742	usd
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	19800	usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	634402623	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	503525051	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	503525051	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	634403	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	503525	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	127137483	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126532063	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142517282	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139801924	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14745396	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-12766336	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68039	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50999	usd
CY2022	us-gaap	Revenues Revenues	82049	usd
CY2021	us-gaap	Revenues Revenues	200749	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23767	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	52030	usd
CY2022	us-gaap	Gross Profit GrossProfit	58282	usd
CY2021	us-gaap	Gross Profit GrossProfit	148719	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1778766	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2284577	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1778766	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2284577	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1720484	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2135858	usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	12	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-151410	usd
CY2022	us-gaap	Interest Expense InterestExpense	689977	usd
CY2021	us-gaap	Interest Expense InterestExpense	1000148	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-447494	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1137459	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1151558	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2857943	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3287416	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2857943	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3287416	usd
CY2022	usrm	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	0
CY2021	usrm	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.01
CY2022	usrm	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	591558288	shares
CY2021	usrm	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	460794491	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11579292	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	128000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	641688	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	275000	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	52238	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	375586	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	428556	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3287416	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-12766336	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	48817	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	19511	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	297000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	491607	usd
CY2022	usrm	Common Shares Issued As Equity Kicker For Convertible Notes Payable CommonSharesIssuedAsEquityKickerForConvertibleNotesPayable	18563	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	25000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	85000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	134974	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2857943	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-14745396	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2857943	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3287416	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	616	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	93241	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	685326	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	977386	usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	12	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-151410	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-447494	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-750000	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-422722	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	384380	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	556556	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3735	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	40290	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	587	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5025	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	274268	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	73195	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	18341	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6768	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-3000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-3000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-304852	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1057939	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	275000	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	186210	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	90000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	17618	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	27000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	766000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10000	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	270592	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1078762	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-34260	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	20823	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39393	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18570	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5133	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39393	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6113	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	22762	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	384174	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	47594	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	25000	usd
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	375586	usd
CY2022	usrm	Common Shares Issued As Equity Kicker For Convertible Notes Payable CommonSharesIssuedAsEquityKickerForConvertibleNotesPayable	18563	usd
CY2021	usrm	Common Shares Issued As Equity Kicker For Convertible Notes Payable CommonSharesIssuedAsEquityKickerForConvertibleNotesPayable	0	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	19511	usd
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	19800	usd
CY2022	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	8250	usd
CY2021	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	0	usd
CY2022	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	usd
CY2021	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	641688	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE 1 </b>—<b> NATURE OF OPERATIONS</b></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient-based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of cell therapy clinics. To date, the Company has not generated significant revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise.</p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5133	usd
CY2022Q4	usrm	Working Capital Deficit WorkingCapitalDeficit	-14009852	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2857943	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-304852	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	224203	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	160680338	shares
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include stock-based compensation, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	75000	usd
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	129623891	shares
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	56500	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	59500	usd
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	100000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	384174	usd
CY2022	usrm	Convertible Debt Discount Increase Decrease ConvertibleDebtDiscountIncreaseDecrease	241589	usd
CY2022	usrm	Retained Earnings Increase Decrease RetainedEarningsIncreaseDecrease	142585	usd
CY2022Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	756437	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	644670	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1746990	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1227588	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	79132	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	79132	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2582559	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1951390	usd
CY2021Q1	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	100000	usd
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	100000	usd
CY2021Q1	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	100000	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	166424	usd
CY2021Q4	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1500	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6000	usd
CY2022	usrm	Convertible Debt Discount Increase Decrease ConvertibleDebtDiscountIncreaseDecrease	241589	usd
CY2020Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	35000	usd
CY2020Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2021-02-05
CY2020Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05	pure
CY2020Q1	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price equal to a thirty percent (30%) discount of the average closing price of the Company’s common stock on the OTC Markets electronic exchange for the prior thirty (30) trading days prior to conversion
CY2022Q1	us-gaap	Debt Instrument Repurchased Face Amount DebtInstrumentRepurchasedFaceAmount	214000	usd
CY2022Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0	pure
CY2022Q1	us-gaap	Debt Instrument Interest Rate Increase Decrease DebtInstrumentInterestRateIncreaseDecrease	0.12	pure
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	44113	usd
CY2022Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	27000	usd
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	6750000	shares
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-447494	usd
CY2022Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	25000	usd
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	3125000	shares
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10000	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2022Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	115000	usd
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	7518797	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	34522	shares
CY2015Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	100000	usd
CY2020Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2035820	shares
CY2020Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10179	usd
CY2020Q4	us-gaap	Paid In Kind Interest PaidInKindInterest	9195	usd
CY2020Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-984	usd
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	187575	shares
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	10879	usd
CY2021Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	9145	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1734	usd
CY2021Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	743341	shares
CY2021Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	8921	usd
CY2021Q4	us-gaap	Paid In Kind Interest PaidInKindInterest	9195	usd
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	274	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1121154	shares
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	9866	usd
CY2022Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	9144	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	722	usd
CY2022Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1377891	shares
CY2022Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	9645	usd
CY2022Q4	us-gaap	Paid In Kind Interest PaidInKindInterest	9195	usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	450	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	3894200	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	3144200	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6541	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4711	usd
CY2022	us-gaap	Lease Cost LeaseCost	6541	usd
CY2021	us-gaap	Lease Cost LeaseCost	4711	usd
CY2016Q4	usrm	Royalty Agreement Term RoyaltyAgreementTerm	P25Y
CY2016Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	75000	usd
CY2016Q4	usrm	Percentage Of Revenues To Be Received As Royalty PercentageOfRevenuesToBeReceivedAsRoyalty	0.05	pure
CY2016	us-gaap	General Insurance Expense GeneralInsuranceExpense	100000	usd
CY2017	us-gaap	General Insurance Expense GeneralInsuranceExpense	11000	usd
CY2022Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	25810	usd
CY2021Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	26600	usd
CY2020Q2	us-gaap	Notes Payable NotesPayable	1397762	usd
CY2019Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0525	pure
CY2019Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	500000	usd
CY2019Q2	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	5000	usd
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	500000	usd
CY2021Q1	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	100000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	384174	usd
CY2022	usrm	Convertible Debt Discount Increase Decrease ConvertibleDebtDiscountIncreaseDecrease	241589	usd
CY2022	usrm	Retained Earnings Increase Decrease RetainedEarningsIncreaseDecrease	142585	usd
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	4000000	shares
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	128000	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	28891144	shares
CY2021Q3	usrm	Common Stock Registered Shares CommonStockRegisteredShares	250000000	shares
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	27500000	shares
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	275000	usd
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	45000000	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	297000	usd
CY2022Q1	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	extended for two years
CY2022Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	53400000	shares
CY2022Q1	usrm	Class Of Warrant Or Rights Granted ClassOfWarrantOrRightsGranted	12500000	shares
CY2022Q1	usrm	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted	0.008
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	491607	usd
CY2022Q1	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	294000	usd
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	44113	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	447494	usd
CY2022Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	25000	usd
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	25000	usd
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	3125000	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	13958334	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85000	usd
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	111119914	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0247
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	296636	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	476030	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.0298
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	110643884	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0247
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	36686	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2500	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.154
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	110641384	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0247
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5500	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	104816384	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.0258
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5500	usd
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	110641384	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.0247
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	104816384	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.0258
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1110468	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.84
CY2020	usrm	Class Of Warrants Or Rights Warrants Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsWarrantsOutstandingWeightedAverageRemainingContractualTerm	P7Y1M6D
CY2021	usrm	Class Of Warrant Or Rights Granted ClassOfWarrantOrRightsGranted	0	shares
CY2021	usrm	Class Of Warrant Or Rights Exercised ClassOfWarrantOrRightsExercised	0	shares
CY2021	usrm	Class Of Warrant Or Rights Expired ClassOfWarrantOrRightsExpired	-7341	shares
CY2021	usrm	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExpired	77.88
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1103127	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.41
CY2021	usrm	Class Of Warrants Or Rights Warrants Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsWarrantsOutstandingWeightedAverageRemainingContractualTerm	P6Y2M12D
CY2021	usrm	Aggregate Intrinsic Value Of The Issued And Exercisable Warrants AggregateIntrinsicValueOfTheIssuedAndExercisableWarrants	0	usd
CY2022	usrm	Class Of Warrant Or Rights Granted ClassOfWarrantOrRightsGranted	12500000	shares
CY2022	usrm	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted	0.008
CY2022	usrm	Class Of Warrant Or Rights Expired ClassOfWarrantOrRightsExpired	-20000	shares
CY2022	usrm	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExpired	15.5
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13583127	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.99
CY2022	usrm	Class Of Warrants Or Rights Warrants Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsWarrantsOutstandingWeightedAverageRemainingContractualTerm	P4Y3M18D
CY2022	usrm	Aggregate Intrinsic Value Of The Issued And Exercisable Warrants AggregateIntrinsicValueOfTheIssuedAndExercisableWarrants	0	usd
CY2022Q4	usrm	Class Of Warrant Or Rights Exercisable ClassOfWarrantOrRightsExercisable	13581582	shares
CY2022Q4	usrm	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable	0.12
CY2022	usrm	Class Of Warrants Or Rights Warrants Exercisable Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsWarrantsExercisableWeightedAverageRemainingContractualTerm	P4Y3M18D
CY2022	usrm	Aggregate Intrinsic Value Of The Issued And Exercisable Warrants AggregateIntrinsicValueOfTheIssuedAndExercisableWarrants	0	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13583127	shares
CY2022	usrm	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding	0.99
CY2022	usrm	Class Of Warrants Or Rights Warrants Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsWarrantsOutstandingWeightedAverageRemainingContractualTerm	P4Y3M18D
CY2022Q4	usrm	Class Of Warrant Or Rights Exercisable ClassOfWarrantOrRightsExercisable	13581582	shares
CY2022Q4	usrm	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable	0.12
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1263199	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	843633	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	261362	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	174551	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1524561	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1018184	usd
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-1524561	usd
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-1018184	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20187838	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22139733	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4405938	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4371729	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1213463	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1023375	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	157661	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	155710	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	260012	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	154546	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	274703	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26379458	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27965250	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	61231	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	61231	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26379458	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27904019	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	79700000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	87400000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	5700000	usd
CY2021	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	limited to 80% of taxable income in the year utilized
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by Section 382 of the Code, the Company’s net operating loss carryforwards may be significantly limited as to the amount of use in a particular year.
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-600168	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-690357	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-92413	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-137277	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-61231	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	166437	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements Other IncomeTaxReconciliationTaxSettlementsOther	93974	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements Other IncomeTaxReconciliationTaxSettlementsOther	0	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	52375	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	7175	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	26880	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	2124849	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1652501	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1524561	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1018184	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001388319

Files In Submission

Name	View Source	Status
usrm-20221231_def.xml	Edgar Link	unprocessable
0001185185-23-000339-index-headers.html	Edgar Link	pending
0001185185-23-000339-index.html	Edgar Link	pending
0001185185-23-000339.txt	Edgar Link	pending
0001185185-23-000339-xbrl.zip	Edgar Link	pending
ex_490188.htm	Edgar Link	pending
ex_490189.htm	Edgar Link	pending
ex_490190.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
usrm-20221231.xsd	Edgar Link	pending
usstem20221231_10k.htm	Edgar Link	pending
usstem20221231_10kimg001.jpg	Edgar Link	pending
usrm-20221231_cal.xml	Edgar Link	unprocessable
usrm-20221231_lab.xml	Edgar Link	unprocessable
usrm-20221231_pre.xml	Edgar Link	unprocessable
usstem20221231_10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

U.S. Stem Cell, Inc.

2023 Q2 Form 10-K Financial Statement

#000118518523000339 Filed on April 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission